A chemogenomic approach to drug discovery: focus on cardiovascular diseases

被引:50
作者
Cases, Montserrat
Mestres, Jordi [1 ]
机构
[1] Inst Municipal Invest Med, Chemogenom Lab, Res Unit Biomed Informat, E-08003 Barcelona, Spain
关键词
PHARMACOLOGY; GENOMICS; NETWORK; TARGETS; SPACE;
D O I
10.1016/j.drudis.2009.02.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
References to individual protein targets and bioactive small molecules associated with cardiovascular diseases can be found in multiple bibliographic sources. From mining these sources, a highly curated list of 214 cardiovascular targets was collected and organised using functional classification schemes for the main protein families of therapeutic relevance, namely, enzymes, G-protein-coupled receptors, ion channels, and nuclear receptors. This list was then used to interrogate annotated chemical libraries and extract a chemical space of 44 032 small molecules connected to 160 targets. Some of these bioactive ligands were also found to have affinity for an additional set of 421 proteins not linked originally to cardiovascular diseases, thus constituting a valuable indirect source to complete the cardiovascular target space and infer a potential off-cardiovascular target space.
引用
收藏
页码:479 / 485
页数:7
相关论文
共 36 条
[1]   The properties of known drugs .1. Molecular frameworks [J].
Bemis, GW ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2887-2893
[2]   The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data [J].
Berman, Helen ;
Henrick, Kim ;
Nakamura, Haruki ;
Markley, John L. .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D301-D303
[3]   GoPubMed: Exploring PubMed with the gene ontology [J].
Doms, A ;
Schroeder, M .
NUCLEIC ACIDS RESEARCH, 2005, 33 :W783-W786
[4]   Techniques: Cardiovascular pharmacology and drug discovery in the 21st century [J].
Douglas, SA ;
Ohlstein, EH ;
Johns, DG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (04) :225-233
[5]   In silico pharmacology for drug discovery:: methods for virtual ligand screening and profiling [J].
Ekins, S. ;
Mestres, J. ;
Testa, B. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (01) :9-20
[6]   FCP:: functional coverage of the proteome by structures [J].
Garcia-Serna, Ricard ;
Opatowski, Lulla ;
Mestres, Jordi .
BIOINFORMATICS, 2006, 22 (14) :1792-1793
[7]   A ligand-based approach to mining the chemogenomic space of drugs [J].
Gregori-Puigjane, Elisabet ;
Mestres, Jordi .
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2008, 11 (08) :669-676
[8]   Preclinical cardiovascular risk assessment in modern drug development [J].
Guth, Brian D. .
TOXICOLOGICAL SCIENCES, 2007, 97 (01) :4-20
[9]   Privileged molecules for protein binding identified from NMR-based screening [J].
Hajduk, PJ ;
Bures, M ;
Praestgaard, J ;
Fesik, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (18) :3443-3447
[10]   Chemogenomics: structuring the drug discovery process to gene families [J].
Harris, C. John ;
Stevens, Adrian P. .
DRUG DISCOVERY TODAY, 2006, 11 (19-20) :880-888